Urovant Sciences (UROV) announced that the FDA had accepted its New Drug Application ((NDA)) for its drug vibegron for the treatment of patients with overactive bladder ((OAB)). The expected catalyst for the FDA to review the drug is not expected until the end of 2020, but the biotech is working on advancing several other indications for overactive bladder. Not only that, but it is working on a separate gene therapy product URO-902 for patients who had previously failed with other prior therapies. With the company's main focus being on helping patients with overactive